Stephen B. Shrewsbury

Chief Medical Officer, MAP Pharmaceuticals, Inc.

Companies

Impel Neuropharma (United States)Chief Medical Officer Apr 22, 2021 to Mar 30, 2022¹
Neurogene Inc.CMO; Senior VP Clinical Dev. Mar 6, 2014 to Mar 14, 2016²
Sarepta TherapeuticsSVP/Regulatory Affairs Jan 28, 2009 to Aug 24, 2010³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Impel Neuropharma (United States)97,990 shares⁴Mar 29, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 29, 2022Exercised options 24,606 shares at $1.97 of Impel Neuropharma (United States)⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARImpel Neuropharma (United States), Chief Medical Officer
2
SEC EDGARNeurogene Inc., CMO; Senior VP Clinical Dev.
3
SEC EDGARSarepta Therapeutics, SVP/Regulatory Affairs
4
SEC EDGARImpel Neuropharma (United States) shares after the filing of Mar 29, 2022